Table 1 Clinicobiological characteristics of the studied cohort.
All cases | Binet A | Binet A M-CLL | Binet A U-CLL | |
|---|---|---|---|---|
Gender | ||||
Male | 2890 (63%) | 1992 (59%) | 1183 (58%) | 708 (61%) |
Female | 1690 (37%) | 1370 (41%) | 862 (42%) | 445 (39%) |
Median age at diagnosis (years) | 64.6 | 64.9 | 64.6 | 64.9 |
IGHV gene SHM status | ||||
M-CLL | 2454 (57%) | 2045 (64%) | ||
U-CLL | 1878 (43%) | 1153 (36%) | ||
Unknown | 239 | 164 | ||
Recurrent aberrationsa | ||||
del(13q) | 1856 (42%) | 1465 (45%) | 775 (57%) | 302 (27%) |
trisomy12 | 566 (13%) | 380 (12%) | 72 (5%) | 212 (19%) |
del(11q) | 495 (11%) | 277 (8%) | 12 (1%) | 225 (20%) |
del(17p) | 236 (5%) | 148 (5%) | 42 (3%) | 78 (7%) |
No recurrent abnormalities | 1306 (29%) | 1005 (31%) | 469 (34%) | 319 (28%) |
Unknown | 121 | 87 | 35 | 17 |
Binet stage | ||||
A | 3362 (74%) | |||
B | 825 (18%) | |||
C | 387 (8%) | |||
Unknown | 6 | |||
Treatment statusb | ||||
Treated | 2680 (59%) | 1570 (47%) | 640 (32%) | 875 (76%) |
Untreated | 1900 (41%) | 1792 (53%) | 1405 (68%) | 278 (24%) |
